Skip to content
Subscribe
Newsletter
Advertise
MDA.org
Donate
Subscribe
Donate
Menu
Magazine
Current Issue
Past Issues
Featured Content
Topics
Advocacy
Finding a Diagnosis
Get Involved
Health
Inclusion
Independence
Lifestyle
News
Personal Stories
Science + Research
Diseases A-Z
Blog
Podcast
Product Guide
Career Quest
Exon Skipping
Blog Post
2022 Clinical & Scientific Conference: March 16 Highlights
By
Sujatha Gurunathan
|
March 16, 2022
Blog Post
Clinical Trial Alert: Phase 1b/2a Study of WVE-N531 in a Subset of People Living with DMD
By
Sujatha Gurunathan
|
March 11, 2022
Blog Post
Simply Stated: What is Duchenne Muscular Dystrophy?
By
Sujatha Gurunathan
|
February 16, 2022
Blog Post
Muscular Dystrophy Association Awards 18 Grants Totaling Over $1.6 Million for Neuromuscular Disease Research
By
Sujatha Gurunathan
|
November 5, 2021
Blog Post
FDA Approves Sarepta Therapeutics’ Amondys 45 for Treatment of DMD Amenable to Skipping Exon 45
By
Sujatha Gurunathan
|
February 25, 2021
Blog Post
Once a Wild Idea, Successful First-Generation Exon-Skipping Therapies Pave the Way for Personalized Treatments
By
Sujatha Gurunathan
|
November 17, 2020
Blog Post
FDA Accepts Sarepta Therapeutics’ New Drug Application for DMD Treatment Casimersen
By
Sujatha Gurunathan
|
August 26, 2020
Blog Post
FDA Approves NS Pharma’s Viltepso for Treatment of DMD Amenable to Exon 53 Skipping
By
MDA Staff
|
August 12, 2020
Blog Post
NS Pharma Announces Positive Results from Phase 2 Study of Viltolarsen in DMD
By
Sujatha Gurunathan
|
June 3, 2020
Blog Post
Pfizer Announces Positive Results from Phase 1b Study of PF-06939926 for Treatment of DMD
By
Sujatha Gurunathan
|
June 1, 2020
« Previous
1
2
3
4
Next »
Skip to content
Open toolbar
Accessibility Tools
Accessibility Tools
Increase Text
Increase Text
Decrease Text
Decrease Text
Grayscale
Grayscale
High Contrast
High Contrast
Negative Contrast
Negative Contrast
Light Background
Light Background
Links Underline
Links Underline
Readable Font
Readable Font
Reset
Reset
